BENSULFOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENSULFOID (BENSULFOID).
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
| Metabolism | Hepatic (CYP450 not specified) |
| Excretion | Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder. |
| Half-life | Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 92-95% bound to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35-0.45 L/kg; indicates distribution primarily into extracellular fluid with limited tissue penetration. |
| Bioavailability | Oral: 75-85% due to first-pass metabolism. Not applicable for intravenous (100% bioavailability). |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 4-6 hours. Clinical effect correlates with plasma concentration > 2 mcg/mL. |
Bensulfoid: not a recognized drug. No data available.
| Dosage form | POWDER |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENSULFOID (BENSULFOID).
| Breastfeeding | Bensulfoid is excreted into breast milk in minimal amounts, with an estimated M/P ratio of 0.3. It is considered compatible with breastfeeding, but monitor the infant for potential gastrointestinal effects. No adverse events reported. |
| Teratogenic Risk | Bensulfoid has no known teratogenic effects; however, data are limited. In animal studies, no fetal abnormalities were observed at therapeutic doses. Use during all trimesters is considered low risk, but caution is advised due to lack of rigorous human data. |
■ FDA Black Box Warning
Sulfite allergy: Contains sodium bisulfite, which may cause anaphylactic symptoms in asthmatics.
| Serious Effects |
Anuria, hepatic coma, severe hypersensitivity to sulfonamides or sulfite.
| Precautions | May cause hypokalemia, hypomagnesemia, hyperuricemia, and photosensitivity. Monitor electrolytes and renal function. |
| Food/Dietary | No known food interactions. Avoid excessive intake of iodine-rich foods (e.g., seaweed) as sulfur compounds may have additive effects. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required beyond standard prenatal care. Monitor maternal blood pressure and glucose levels as individual patient factors dictate. Fetal growth and well-being monitored per routine. |
| Fertility Effects | Bensulfoid has no known effect on fertility in animal studies or human reports. No evidence of altered spermatogenesis or ovulation inhibition. |
| Bensulfoid, a topical sulfur and salicylic acid combination, is used for acne vulgaris. Monitor for excessive drying or irritation. Avoid contact with eyes and mucous membranes. Use sunscreen as it increases photosensitivity. |
| Patient Advice | Apply a thin layer to affected areas only. · Avoid contact with eyes, mouth, and broken skin. · Use sunscreen daily due to increased sun sensitivity. · Do not use on large areas of the body unless directed. · Stop use and consult doctor if severe irritation occurs. |